Skip to main content
. Author manuscript; available in PMC: 2021 Jun 1.
Published in final edited form as: Urol Oncol. 2020 Apr 3;38(6):604.e9–604.e17. doi: 10.1016/j.urolonc.2020.02.029

Figure 1.

Figure 1.

Kaplan-Meier analysis of OS in mRCC patients treated with IO, stratified by receipt of CN. Median OS for CN+IO was not reached, versus 11.6 months (95% CI 8.5–14.7 months) for IO alone (HR 0.23 [95% CI 0.15–0.37], log-rank p<0.001).